Review Article Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers
|
|
- Damian Dennis
- 5 years ago
- Views:
Transcription
1 Pathology International 2006; 56: doi: /j x Review Article Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers Masahiro Maeda 1 and Okio Hino 2 1 Immuno-Biological Laboratories, Fujioka, Gunma and 2 Department of Pathology, Juntendo University, School of Medicine, Tokyo, Japan Mesothelioma is an aggressive tumor arising from the mesothelium, and is usually associated with previous exposure to asbestos. The incubation period of the tumor may be described as years, and the prognosis is dismal. In addition to immunohistochemical markers, recently, serum markers for the diagnosis of mesothelioma have been reported as candidates. In contrast, the expression in renal carcinoma (ERC) gene has been discovered in the Eker rat model (Tsc2 gene mutant), which is a homolog of the human mesothelin/megakaryocyte potentiating factor gene, and a novel ELISA system (N-ERC/mesothelin) has been developed. It has also been found that N-ERC/mesothelin is very stable and plentiful in the blood. In the present paper the potential utility of molecular diagnostic markers is reviewed, including ELISA systems for asbestos-related mesothelioma. Key words: asbestos, ELISA, ERC/mesothelin/MPF, mesothelioma, tumor marker Mesothelioma is an aggressive tumor arising from the mesothelium, a membrane lining several body cavities, including the pleura, peritoneum and pericardium, and is usually associated with asbestos exposure. There are mainly three types of mesothelioma according to site of origin: pleural mesothelioma; peritoneal mesothelioma; and pericardial mesothelioma. Pleural mesothelioma is the most common form of mesothelioma. In the classification based on histological categories, mainly three types of mesothelioma are reported: epithelial; sarcomatous; and mixed. Although epithelial mesothelioma has a better prognosis, the histological distinction between epithelial mesothelioma and Correspondence: Okio Hino, MD, PhD, Department of Pathology, Juntendo University School of Medicine, Hongo, Bunkyo-ku, Tokyo , Japan. ohino@med.juntendo.ac.jp Received 23 July Accepted for publication 26 July adenocarcinomas/sarcomatous mesothelioma and sarcomas is often difficult and requires additional immunohistochemial studies. Asbestos is the commercial name for a group of hydrated magnesium silicate fibrous minerals. Three types are mainly recognized: Chrysotile (white asbestos), Crocidolite (blue asbestos), and Amosite (brown asbestos). Asbestos is valued in the industry for its resistance to heat and combustion, and has been used in the production of cement, ceiling and pool tiles, automobile brake linings, and shipbuilding. Several types of asbestos-related illnesses other than mesothelioma are known: pleural plaques, pleural thickening, asbestosis and lung cancer. In Japan the amount of asbestos imports increased between 1960 and 1974, and reached a peak in However, an increased risk of developing mesothelioma was later found among people who work with asbestos. With the increase of asbestos imports, the number of deaths from pleural mesothelioma has grown. Since the early 1990s an exponential increase has been observed: the estimated mean annual number of deaths from malignant pleural mesothelioma (MPM) was 506 between 1995 and 1999, and approximately 1000 in Given that the latency of mesothelioma is described as years, its incidence is expected to increase in the coming decades. IMMUNOHISTOCHEMICAL MARKERS FOR MESOTHELIOMA The most important modalities for the diagnosis of mesothelioma are chest radiography, chest CT, and magnetic resonance imaging (MRI) of the chest. However, it may be difficult to make an early diagnosis of mesothelioma using the currently available diagnostic imaging techniques, and identification of tumor markers is urgently needed. Immunohistochemical diagnosis of epithelioid mesothelioma
2 650 M. Maeda and O. Hino in pleural biopsy or surgically resected specimens has been actively pursued, using markers such as podoplanin, calretinin, WT-1, cytokeratin 5, thrombomodulin, and mesothelin. 2,3 Some of these markers have indeed been helpful for confirming the diagnosis of mesothelioma and distinguishing between mesothelioma and adenocarcinoma, which is one of the challenging problems for surgical pathologists. Ordonez reported a comparison of the various immunohistochemical markers currently available for the diagnosis of mesothelioma and squamous carcinoma of the lung. 4 A total of 30 epithelioid pleural mesotheliomas and 30 non-keratinizing squamous carcinomas of the lung were investigated for the expression of the following markers: podoplanin, calretinin, mesothelin, WT1, keratin 5/6, keratin 7, p63, CEA, MOC-31, Ber-EP4, B72.3, BG-8 (Lewisy), leu-m1 (CD15), and thyroid transcription factor-1 (TTF-1). All 30 (100%) of the mesotheliomas reacted for calretinin, mesothelin and keratin 7, 93% each for podoplanin, WT1 and keratin 5/6, 13% for Ber-EP4, 7% each for p63, MOC-31 and BG-8, and 0% for B72.3, CEA, leu-m1 and TTF-1. All 30 (100%) of the squamous carcinomas were positive for p63 and keratin 5/6, 97% for MOC-31, 87% for Ber-EP4, 80% for BG-8, 77% for CEA, 57% for keratin 7, 40% for calretinin and B72.3, 30% for leu-m1, 27% for mesothelin, 15% for podoplanin, and 0% for WT 1 and TTF-1. As a result, a combination of two positive mesothelioma markers (WT1 and calretinin or mesothelin) with two negative mesothelioma markers (p63 and MOC-31) would allow the differential diagnosis to be established between epithelioid mesotheliomas and squamous carcinomas of the lung in nearly all instances (cited in Ordonez 4 ). Also, Yaziji et al. evaluated the sensitivity and specificity of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma using immunohistochemistry. 5 The antibodies against thrombomodulin and HBME-1 were in addition to those used by Ordonez, aforedescribed. The 143 tumors evaluated included 65 malignant epithelioid mesotheliomas, 22 lung adenocarcinomas, 27 ovarian serous carcinomas, 24 breast carcinomas, and five gastric carcinomas. Calretinin had the best sensitivity for mesothelioma (95%), followed by HBME-1 (84%), WT-1 (78%), cytokeratin 5 (76%), mesothelin (75%), and vimentin and thrombomodulin (68%). Thrombomodulin had the best specificity for mesothelioma (92%), followed by cytokeratin 5 (89%), calretinin (87%) vimentin (84%), and HBME-1 (45%). When ovarian carcinomas were excluded from the analysis, the specificity of mesothelin and WT-1 for the diagnosis of mesothelioma increased to 90% and 81%, respectively. The specificity of the non-mesothelial antigens for adenocarcinoma was 98% for BG8 and CEA, 97% for CD15, 95% for BerEp4, and 87% for MOC-31 (cited in Yaziji et al. 5 ). Yaziji et al. showed that a three-antibody immunohistochemical panel including calretinin, BG8, and MOC-31, provided 96% sensitivity and specificity for distinguishing epithelioid mesothelioma from adenocarcinoma. 5 In the case of sarcomatous mesothelioma, the histological distinction from synovial sarcoma may be difficult because of the combination of epithelioid and spindle cells, potentially shared locations, and antigenic expression. The differential diagnosis of liposarcomas, leiomyosarcomas, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, gastrointestinal stromal tumor, desmoid tumor, Ewing s sarcoma, osteosarcoma and chondrosarcoma can also be difficult, even though a few markers (e.g. CAM 5.2 etc.). are recommended for differential diagnosis by immunostainning. In immunohistochemical study for mesothelin, 5B2 antibody (Novocastra, Newcastle upon Tyne, UK) is now commonly used. However, the recognition epitope of 5B2 is not defined. We have established polyclonal antimesothelin antibody using the synthetic peptide as immunogen, and performed immunohistochemical study on tissues of mesothelioma patients. As a result, mesothelin is highly expressed in tumor cells (Fig. 1) and membranous reactivity is evident. 6 These trials using antibodies with the well-defined epitopes could elucidate varied presentation of mesothelin molecule in mesothelioma and may be helpful in understanding mesothelioma. Thus, immunohistochemical diagnosis using various antibodies for markers is under intense study. However, there are some differences among them. The standardization of protocols may be required. SERUM MARKERS FOR MESOTHELIOMA While no reliable serum marker for the diagnosis of mesothelioma has as yet been established, Robinson et al. recently proposed soluble mesothelin-related protein (SMRP) as one of the candidates. 7,8 Yamaguchi et al. first reported the purification of megakaryocyte potentiating factor (MPF) protein from the culture supernatant of the human pancreatic cancer cells HPC-Y5. 9 Subsequently, Kojima et al. isolated human MPF cdna from an HPC-Y5 cdna library by polymerase chain reaction using specific primers derived from the amino acid sequences of purified MPF polypeptides and plaque hybridization methods, and reported the same sequence 10 as that reported by Chang and Pastan, 11 described here. Sequence analysis predicted that the 622-amino acid protein contains an N-terminal 33-residue signal sequence and four potential N-glycosylation sites. In contrast, Chang et al. isolated an antigen cdna of MAb K1 that had an 1884 bp open reading frame encoding a 69 kda protein, and showed that a 69 kda protein was the precursor of this 40 kda glycoprotein, with the 40 kda form released by treatment with phosphatidylinositol-specific phospholipase C. 11,12
3 Molecular markers for mesothelioma 651 Figure 1 Immunohistochemical staining for mesothelin using antimesothelin antibody (rabbit IgG) in pleural mesothelioma specimens. Mesothelin protein was expressed highly in tumor cells and membranous reactivity was evident. Figure 2 Schematic diagram of production and digestion of ERC/ mesothelin, and ELISA system. The primary product of the ERC/ mesothelin gene is a 71 kda precursor protein. This protein is cleaved physiologically, releasing its 31 kda N-terminal fragment, designated as N-ERC/mesothelin, into the blood. The 31 kda N-terminal fragment is detected by a sandwich ELISA system containing two antibodies against the N-terminal fragment. Scholler et al. reported that the antigen protein recognized by mab OV569 had an identical N-terminal amino acid sequence to that of the membrane-bound portion of mesothelin and MPF; 13 this kda protein was termed a soluble member(s) of the mesothelin/megakaryocyte potentiating factor family related protein (SMRP). SMRP has an 82 bp insertion in the membrane-associated part and codes for a C terminus with a hydrophilic, presumably soluble, tail. Robinson et al. and Creaney and Robinson reported that the serum concentrations of SMRP measured using a double determinant (sandwich) ELISA could be a useful marker for the diagnosis of mesothelioma and for monitoring the disease progression in cases of mesothelioma. 7,8,14 We have previously reported the identification of the expressed in renal carcinoma (ERC) gene, which is strongly expressed in renal cancers in the Eker rat, which develops hereditary renal carcinomas following the induction of two-hit mutations of tumor suppressor genes. 15,16 A database search showed that this predicted amino acid from ERC cdna had 87.4% and 56.1% identity, respectively, to the mouse and human mesothelin gene. Therefore, henceforth, we shall refer to this protein as ERC/mesothelin. The human mesothelin gene codes for several proteins; the primary product is a 71 kda precursor protein that can be physiologically cleaved by some furin-like proteases into a 40 kda C-terminal fragment that remains membrane-bound, and a 31 kda N-terminal fragment, which is secreted into the blood (Fig. 2). The C-terminal 40 kda fragment is referred to as mesothelin. In contrast, the N-terminal 31 kda fragment is a secreted protein identified as MPF. In avoiding confusion arising from the use of the term mesothelin, we shall use the term N-ERC/mesothelin for the N-terminal 31 kda fragment, which is the same as MPF, and C-ERC/mesothelin for the C-terminal 40 kda fragment. ELISA SYSTEMS FOR THE DETECTION OF C-ERC/MESOTHELIN Although its real physiological role is still unclear, ERC/ mesothelin has been identified in the serum of not only normal, but also of cancer patients. So far, two groups have reported on ELISA systems for the detection of C-ERC/ mesothelin. Robinson et al. have established an ELISA system for the detection of SMRP. In their first paper they assayed the serum concentrations of SMRP in serum samples obtained from 44 patients with histologically proven mesothelioma, 68 matched healthy controls, 40 of whom had a history of exposure to asbestos, and 160 patients with other inflammatory or malignant lung or pleural diseases. 7 They showed that 84% of the 44 mesothelioma patients had elevated serum concentrations of SMRP, as compared with 2% of the 160 with other lung/pleural diseases. In their second paper they reported that measurement of the concentrations of SMRP in the serum as a marker of mesothelioma had a sensitivity of 83% and specificity of 95% for the diagnosis of mesothelioma in the first 48 mesothelioma patients examined. 8 Scherpereel et al. reported their data obtained using this ELISA kit (Mesomark; Fujirebio Diagnostic, Malvern, PA, USA). 17 The mean serum SMRP level was higher in patients with mesothelioma ( nmol/l, n = 28) than in
4 652 M. Maeda and O. Hino those with pleural metastasis ( nmol/l, n = 35) or benign lesions of the pleura ( nmol/l, n = 28). The pleural fluid SMRP concentrations were higher than the serum SMRP concentrations in all the patient groups (mesothelioma, nmol/l; benign lesions, nmol/l; metastasis, nmol/l). Hassan et al. have pursued the development of mab against ERC/mesothelin. Some of these antibodies have been applied for the treatment of mesothelioma by the immunotoxin technology. 18 Recently, they have produced new mab against C-ERC/mesothelin 19 and an ELISA system for the detection of C-ERC/mesothelin using these mab, and they reported elevated serum levels of mesothelin in 40 of 56 (71%) mesothelioma patients and 14 of 21 (67%) ovarian cancer patients. 20 The serum levels of mesothelin were increased in 80% of patients who had positive tumor immunohistochemistry for mesothelin. They also observed a rapid decrease in the serum mesothelin levels after surgery in patients with peritoneal mesothelioma. Thus, several ELISA systems have been evaluated for measurement of the serum levels of C-ERC/mesothelin as a possible diagnostic marker for mesothelioma. However, some questions on the measurement of C-ERC/mesothelin remain. First, the mechanisms related to increase of C-ERC/ mesothelin release from the mesothelioma cell surface have not yet been elucidated. While N-ERC/mesothelin represents the secretory form, the remaining C-ERC/mesothelin part of the molecule is still membrane-bound. The release of mesothelin from the cell surface is probably mediated by phospholipase C. There might be mechanisms by which this portion of the molecule is also released to induce tumor progression. Second, the ELISA system for SMRP could detect higher levels of serum SMRP in mesothelioma patients. However, the existence of SMRP (82 bp inserted splicing isoform and other spliced forms) has not yet been demonstrated in the serum of mesothelioma patients. Recently, Hellstrom et al. reported the establishment of specific mab and ELISA systems for each of three variants of ERC/mesothelin, 1, 2 and 3, which had an 82 bp insert within the C-ERC/ mesothelin region. 21 In that study, purification and analysis of the ERC/mesothelin variants from the ascitic fluid of ovarian cancer patients using immunoaffinity chromatography with mab 569 showed ERC/mesothelin variants 1 and 2, but not 3. The same approach should be used in mesothelioma patients. digestion is inhibited by furin inhibitors (Fig. 2). A mutated variant of ERC/mesothelin, in which an amino acid in the furin recognition site was substituted by alanine, was not digested by furin, even when expressed in mammalian cells (data not shown). These data have confirmed the processing pathway of the ERC/mesothelin protein. Therefore, we have focused on N-ERC/mesothelin, because N-ERC/mesothelin can probably be detected earlier and with higher sensitivity in cases of mesothelioma than C-ERC/mesothelin. We have developed a novel ELISA system for the detection of N-ERC/mesothelin in the serum of mesothelioma patients, and have begun to examine its clinical usefulness. 6 Mouse monoclonal antibodies (clone 7E7) and rabbit polyclonal antibodies (PoAb-282) were raised against human N-ERC/mesothelin and used for the establishment of the ELISA system. Serum samples from seven patients with mesothelioma, four patients with carcinomatous pleuritis pleural metastasis (lung cancer), three with benign asbestos pleuritis, and 13 healthy volunteers were evaluated. The diagnosis in patients with mesothelioma was confirmed immunohistochemically (all epithelial types). The median serum concentrations in the seven mesothelioma patients, 13 healthy controls, four pleural metastasis (lung cancer) patients and three benign asbestos pleuritis patients were ng/ml (range: ng/ml), 1.4 ng/ml (range: ng/ml), 1.31 (range: ng/ml), and 1.10 ng/ml (range: ng/ml), respectively (Fig. 3). Until now, our ELISA system has detected much higher serum levels of N-ERC/mesothelin in mesothelioma patients than in healthy controls or patients with other lung/pleural diseases. NOVEL ELISA SYSTEM FOR N-ERC/MESOTHELIN The 31 kda N-ERC/mesothelin is secreted into the blood after cleavage by furin-like proteases, and ERC/mesothelin Figure 3 Scatter plot of serum N-ERC/mesothelin. The serum concentrations of N-ERC/mesothelin were much higher in mesothelioma patients than in the healthy controls, carcinomatous pleuritis (lung cancer) patients and benign asbestos pleuritis patients (cited in Shiomi et al. 6 ).
5 Molecular markers for mesothelioma 653 We propose to conduct a prospective study to establish the clinical utility of our sandwich ELISA system and to determine the relationship between the serum N-ERC/mesothelin concentrations and the clinicopathological features of the patients, cut-off values, and the sensitivity/specificity of the measurement, to explore the possibility of early diagnosis. Recently, Onda et al. also reported the generation of anti- MPF monoclonal antibodies and the development of ELISA to MPF (N-ERC/mesothelin). 22 Their ELISA data showed that MPF levels were elevated in 91% of patients (51 of 56) with mesothelioma compared with healthy controls. Furthermore, MPF levels decreased in patients after tumor debulking surgery. Thus, N-ERC/mesothelin may represent a promising tumor marker for mesothelioma. NOVEL MOLECULAR MARKER: PERSPECTIVE FOR THE FUTURE Although mesothelioma is typically associated with asbestos exposure, the basic roles or physiological functions and relationship with carcinogenesis of ERC/mesothelin remain to be resolved. It was recently reported that mesothelioma is highly likely to be caused by asbestos exposure in genetically predisposed individuals in a certain limited area. 23 There is also the possibility of existence of mesothelioma susceptibility genes. Ramos-Nino et al. reported that the simian virus 40 (SV40) T-antigen (Tag) is present in a large percentage of human mesotheliomas. 24 Approximately half of mesotheliomas in the USA are positive for SV40 Tag. Moreover, in recent epidemiological studies, the hazard ratio for risk of developing mesothelioma due to asbestos exposure alone, or SV40 alone, was compared with the hazard ratio due to asbestos exposure plus SV40 infection. The combination of SV40 infection plus asbestos exposure produced a risk of developing mesothelioma 27-fold higher than that of subjects with asbestos exposure alone. That study provides epidemiological support for a possible cocarcinogenic link between SV40 infection and asbestos exposure in the development of mesothelioma (cited in Ramos-Nino et al. 24 ). To clarify potential molecular and pathological pathways in mesothelioma, large-scale transcriptional studies using microarrays have been reported. 25,26 Gordon et al. reported on transcriptional profiling using high-density oligonucleotide microarrays containing approximately genes to elucidate potential molecular and pathobiological pathways in MPM using discarded human MPM tumor specimens (n = 40). 25 Microarray gene expression data were confirmed using quantitative reverse transcriptase polymerase chain reaction and protein analysis for three novel candidate oncogenes (NME2, CRI1, and PDGFC) and one candidate tumor suppressor (GSN). The NME2 gene is a transcriptional regulator with diverse functions that binds and cleaves DNA via covalent bond formation and catalyzes phosphoryl transfer. The high levels of NME2 are mutagenic. NME2 protein has been shown to bind single-stranded telomeric DNA and the RNA component of telomerase. CRI1 is a cyclic AMP response element-binding protein (CREB)-binding protein and potential oncogene that antagonizes the action of prb, p300, and CREB-binding protein (CBP) histone acetylase activity. Platelet-derived growth factor-c (PDGFC) is described as a novel transforming growth factor that participates in an autocrine signaling loop. Gelsolin (GSN) is known to be downregulated in multiple neoplasms and is capable of suppressing tumorigenicity by inhibiting protein kinase C activation (cited in Gordon et al. 25 ). Combination of these results may explain the tumorigenesis and/or pathology of mesothelioma. Moreover, these high-throughput gene expression data on mesothelioma could provide novel candidates for diagnostic markers for mesothelioma. In clinical practice, pathological diagnosis by trained pathologists using authorized markers is still conducted in pleural biopsy specimens obtained by thoracoscopy. However, it is absolutely essential to establish a method for the early diagnosis or screening of malignant mesothelioma, because of the long incubation period and absence, until now, of effective therapeutic modalities for the tumor. ERC/ mesothelin may be a probable candidate for an early serum marker of mesothelioma. In a recent report, serum osteopontin was evaluated as a marker for mesothelioma. 27 However, the concentrations of osteopontin in the serum do not represent the actual serum concentrations of osteopontin, because osteopontin is cleaved by thrombin, a component of the blood coagulation. Furthermore, elevation of the serum osteopontin level is not specific for mesothelioma. Several molecular markers in immunohistochemical and ELISA study for mesothelioma have been developed and must be evaluated in parallel or systematic studies. Retrospective and prospective studies using molecular markers should be conducted in collaboration with imaging diagnosis. ACKNOWLEDGMENTS This work is supported by a Grant-in-Aid for Cancer Research and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports and Science and Technology of Japan and the Ministry of Health, Labor and Welfare of Japan. REFERENCES 1 Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y. Asbestos-related lung cancer and mesothelioma in Japan. Ind Health 2001; 39:
6 654 M. Maeda and O. Hino 2 Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: An update. Arch Pathol Lab Med 2005; 129: Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005; 10: Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: A comparative study. Mod Pathol 2006; 19: Yaziji H, Battifora H, Barry TS et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19: Shiomi K, Miyamoto H, Segawa T et al. A novel ELISA system for detection of a N-ERC/Mesothelin in the sera of mesothelioma patients. Cancer Sci 2006; 97: Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: Robinson BW, Creaney J, Lake R et al. Soluble mesothelinrelated protein: A blood test for mesothelioma. Lung Cancer 2005; 49: S Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994; 269: Kojima T, Oh-eda M, Hattori K et al. Molecular cloning and expression of megakaryocyte potentiating factor cdna. J Biol Chem 1995; 270: Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: Chang K, Pai LH, Pass H et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992; 16: Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999; 96: Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: The potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005; 19: Hino O, Kobayashi E, Nishizawa M et al. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 1995; 121: Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cdna sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 2000; 275: Scherpereel A, Grigoriu B, Conti M et al. Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: Hassan R, Bera T, Pastan I. Mesothelin: A new target for immunotherapy. Clin Cancer Res 2004; 10: Onda M, Willingham M, Nagata S et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005; 11: Hassan R, Remaley AT, Sampson ML et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12: Hellstrom I, Raycraft J, Kanan S et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006; 15: Onda M, Nagata S, Ho M et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006; 12: Dogan AU, Baris YI, Emri S, Steele I, Elmishad AG, Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006; 66: Ramos-Nino ME, Testa JR, Altomare DA et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem 2006; 98: Gordon GJ, Rockwell GN, Jensen RV et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005; 166: Gordon GJ, Rockwell GN, Godfrey PA et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005; 11: Pass HI, Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353:
Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016
Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar
More informationImportance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms
ONCOLOGY LETTERS 9: 1583-1589, 2015 Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms TAKAHIRO EINAMA 1,2,3, HIROFUMI KAMACHI 1, HIROSHI NISHIHARA 4, SHIGENORI
More informationValue of antimesothelioma HBME 1 in the diagnosis of inflammatory and malignant pleural effusions
Romanian Journal of Morphology and Embryology 2006, 47(4):351 355 ORIGINAL PAPER Value of antimesothelioma HBME 1 in the diagnosis of inflammatory and malignant pleural effusions LILIANA MOCANU 1), ANCA
More informationACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION
POL J PATHOL 2011; 2: 95-100 ACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION OF MALIGNANT PLEURAL AND PERITONEAL EFFUSIONS FERESHTEH ENSANI, FARNAZ NEMATIZADEH, GITI IRVANLOU Department of Cytology, Cancer
More informationBiopsy Interpretation of Spindle cell proliferations of the Serosa
Biopsy Interpretation of Spindle cell proliferations of the Serosa Richard Attanoos, Cardiff. U.K. Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee)
More informationMesothelioma Pathobasic. Lukas Bubendorf Pathology
Mesothelioma Pathobasic Lukas Bubendorf Pathology Mechanisms of Asbestos Carcinogenesis in Mesothelioma Asprin High-mobility group protein B1 master switch HMGB1 Initiation/ perpetuation of inflamm. response
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationBiomarkers of asbestos exposure and mesothelioma
University of Hawai i Cancer Center Biomarkers of asbestos exposure and mesothelioma Haining Yang, PhD Professor University of Hawai i Cancer Center MM is a Global l Problem: Millions of people have been
More informationUnderstanding the mechanisms of asbestos related diseases
University of Hawai i Cancer Center Understanding the mechanisms of asbestos related diseases Haining Yang, PhD Professor University of Hawai i Cancer Center Marker of exposure: Bilateral pleural plaques
More informationACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
More informationCombined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma
942 Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma KAZUYA FUKUOKA 1,2, KOZO KURIBAYASHI 3, SHUSAI YAMADA 2, KUNIHIRO TAMURA 2, CHIHARU TABATA
More informationOriginal Article Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry
Pathology International 2008; 58: 75 83 doi:10.1111/j.1440-1827.2007.02193.x Original Article Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry
More informationM alignant mesothelioma is an aggressive, asbestosrelated
569 LUNG CANCER Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma Jenette Creaney, Deborah Yeoman, Leanne K Naumoff, Michelle Hof, Amanda Segal, Arthur William
More informationWell-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report
Showa Univ J Med Sci 25 1, 67 72, March 2013 Case Report Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report Yuri TOMITA
More informationA Useful Antibody Panel for Differential Diagnosis Between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases
Anatomic Pathology / Peritoneal Mesothelioma A Useful Antibody Panel for Differential Diagnosis Between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases Yukio Takeshima, MD, Vishwa
More informationExpression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Peiguo G. Chu, M.D., Ph.D., Lawrence M. Weiss, M.D. Department of Pathology, City of Hope National Medical Center,
More informationFollow up of the Guidelines for Cytopathologic Diagnosis of Malignant Mesothelioma
Follow up of the Guidelines for Cytopathologic Diagnosis of Malignant Mesothelioma Assoc. Prof. Katalin Dobra, Senior Lecturer in Molecular Pathology Karolinska University Hospital Stockholm, Sweden Disclosure
More informationImmunohistochemistry on Fluid Specimens: Technical Considerations
Immunohistochemistry on Fluid Specimens: Technical Considerations Blake Gilks Dept of Pathology University of British Columbia, Vancouver, BC, Canada Disclosures None Learning Objectives At the end of
More informationPRODUCT I N FOR MATION Fujirebio Diagnostics EIA Kit
PRODUCT I N FOR MATION Fujirebio Diagnostics EIA Kit Only available outside the US Working Together for Better Diagnostics Introduction Features and Benefits of EIA kits from Fujirebio Diagnostics Simple
More informationImmunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of lung carcinomas and mesotheliomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Endobronchial ultrasound guided transbronchial needle biopsy
More informationLung Tumor Cases: Common Problems and Helpful Hints
Lung Tumor Cases: Common Problems and Helpful Hints Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona Society of Pathologists
More informationResearch Article Preoperative Serum Levels of Mesothelin in Patients with Colon Cancer
Disease Markers, Article ID 161954, 5 pages http://dx.doi.org/10.1155/2014/161954 Research Article Preoperative Serum Levels of Mesothelin in Patients with Colon Cancer Özgür BostancJ, 1 Özgür Kemik, 2
More informationMalignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry
766 J Clin Pathol 2001;54:766 770 Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry Department of Pathology, Victoria Infirmary, Langside
More informationGUT-C 11/30/2017. Debasmita Das, M.D. PGY-1 Danbury Hospital
GUT-C 11/30/2017 Debasmita Das, M.D. PGY-1 Danbury Hospital CLINICAL SUMMARY 8/2017 59 year old female Presented to the ED with 1 month history of general malaise, fever and weight loss PMH: Significant
More informationEffectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
Eur Respir J 2013; 41: 706 715 DOI: 10.1183/09031936.00226111 CopyrightßERS 2013 REVIEW Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma Ioannis Pantazopoulos*, Paraskevi
More informationEpithelial mesotheliomas can be extremely difficult to distinguish
ORIGINAL ARTICLE The Use of Pleural Fluid scd44v6/std Ratio for Distinguishing Mesothelioma from Other Pleural Malignancies José M. Porcel, MD,* Aureli Esquerda, PharmD, Francisco Rodriguez-Panadero, MD,
More informationDiagnostic IHC in lung and pleura pathology
Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid
More informationWT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic Adenocarcinoma to Body Fluids
Anatomic Pathology / WT1, ESTROGEN RECEPTOR, AND PROGESTERONE RECEPTOR IN CYTOLOGY OF BODY FLUIDS WT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic
More informationClinicopathological Study on Malignant Pleural Mesotheliomas
Table of Contents Clinicopathological Study on Malignant Pleural Mesotheliomas PL-4-03 Kenzo Hiroshima Kenzo Hiroshima 1, Akira Iyota 1, Kiyoshi Sibuya 1, Toshikazu Yusa 2, Takehiko Fujisawa 1 and Yukio
More informationApplications of Flow Cytometry in Diagnostic Cytology of Body Cavity Fluids
Applications of Flow Cytometry in Diagnostic Cytology of Body Cavity Fluids Awtar Krishan, PhD. Professor, Department of Pathology University of Miami School of Medicine akrishan@med.miami.edu Beckman
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationDiscovery of new biomarkers for malignant mesothelioma
Curr Pulmonol Rep (2015) 4:15 21 DOI 10.1007/s13665-015-0106-8 PLEURAL DISEASES AND MESOTHELIOMA (G LEE, SECTION EDITOR) Discovery of new biomarkers for malignant mesothelioma Jenette Creaney & Ian M.
More informationACCME/Disclosures. Case 4 USCAP Pulmonary Panel Case 4 History
Case 4 USCAP Pulmonary Panel 2016 Andrew Churg, MD Department of Pathology Vancouver General Hospital & University of British Columbia Vancouver, BC achurg@mail.ubc.ca. ACCME/Disclosures The USCAP requires
More informationAggressive Malignant Mesothelioma In A Patient Without Previous Asbestos Exposure
ISPUB.COM The Internet Journal of Pathology Volume 19 Number 1 Aggressive Malignant Mesothelioma In A Patient Without Previous Asbestos Exposure A Julai, G Wathuge Citation A Julai, G Wathuge. Aggressive
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationNEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
More informationSerous effusion Objectives. Cytology of Serous Effusions From basics to challenges
Cytology of Serous Effusions From basics to challenges Cytology of Serous Effusions From basics to challenges Pınar Fırat, MD, MIAC Department of Pathology, İstanbul University, İstanbul Faculty of Medicine,
More informationPhospho-AKT Sampler Kit
Phospho-AKT Sampler Kit E 0 5 1 0 0 3 Kits Includes Cat. Quantity Application Reactivity Source Akt (Ab-473) Antibody E021054-1 50μg/50μl IHC, WB Human, Mouse, Rat Rabbit Akt (Phospho-Ser473) Antibody
More informationOriginal Article Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
Pathology International 2007; 57: 190 199 doi:10.1111/j.1440-1827.2007.02080.x Original Article Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
More informationPRODUCT INFORMATION Fujirebio Diagnostics EIA Kit
PRODUCT INFORMATION Fujirebio Diagnostics EIA Kit Only available outside the US Future. The best way to predict the future is to create it. Only by truly understanding the needs of patients, and by collaborating
More informationCase 5 15-year-old male
Case 5 15-year-old male Present illness: Six months ago, abnormality of ECG was incidentally detected by annual health check. His blood level of γ-gtp, HbA1c and norepinephrine were elevated; however,
More informationCell-Adhesion Molecule Expression and the Proliferation of Malignant Mesothelioma: A Post-Mortem Examination
Cell-Adhesion Molecule Expression and the Proliferation of Malignant Mesothelioma: A Post-Mortem Examination KOZO KURIBAYASHI 1*, HIROSHI HIRANO 2*, KEIJI NAKASHO 3, HIDEKI OHYAMA 3, KOJI YAMANEGI 3, CHIHARU
More information5 Biostatistics and Data Management Section, Center for Cancer Research,
Phase 1 Study of the Antimesothelin Immunotoxin SS1P in Combination With Pemetrexed and Cisplatin for Front-Line Therapy of Pleural Mesothelioma and Correlation of Tumor Response With Serum Mesothelin,
More informationCase 2. Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset
Case 2 Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset History 24 year old male presented with a 3 day history of right flank pain, sharp in nature Denies fever, chills, hematuria or
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationKlinisch belang van chromosomale translocatie detectie in sarcomen
Translocations in sarcomas Klinisch belang van chromosomale translocatie detectie in sarcomen Judith V.M.G. Bovée, M.D., Ph.D. Department of Pathology Leiden University Medical Center RNA binding DNA binding
More informationTHYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB
THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB CHARACTERISTIC OF THE IDEAL TUMOR MARKER Specific Sensitive Easy to perform Easy to interpret Adaptable to FNA Reasonable cost (CHEAP) THYROID TUMOR MARKERS
More informationProblem Set 8 Key 1 of 8
7.06 2003 Problem Set 8 Key 1 of 8 7.06 2003 Problem Set 8 Key 1. As a bright MD/PhD, you are interested in questions about the control of cell number in the body. Recently, you've seen three patients
More informationSELECTED DILEMMAS IN RESPIRATORY CYTOPATHOLOGY (2 CASES)
SELECTED DILEMMAS IN RESPIRATORY CYTOPATHOLOGY (2 CASES) Dr. Mariamma Joseph Professor of Pathology Division Head Cytopathology Department of Pathology and Laboratory Medicine LHSC and Western University
More informationSoluble CD155 As A Biomarker For Malignant Bone And Soft Tissue Tumors
Soluble CD155 As A Biomarker For Malignant Bone And Soft Tissue Tumors Mikinobu Goto, MD, Akihiko Matsumine, MD,PhD, Tomoki Nakamura, MD PhD, Takao Matsubara, MD PhD, Kunihiro Asanuma, MD,PhD, Toru Oi,
More informationPathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON
Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON Presentation outline Background and epidemiology of sarcomas Sarcoma classification Sarcoma
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationLoss of Mesothelin Expression by Mesothelioma Cells Grown In Vitro Determines Sensitivity to Anti-Mesothelin Immunotoxin SS1P
Loss of Mesothelin Expression by Mesothelioma Cells Grown In Vitro Determines Sensitivity to Anti-Mesothelin Immunotoxin SS1P JINGLI ZHANG 1, SHUO QIU 1*, YUJIAN ZHANG 1**, MARIA MERINO 2, PATRICIA FETSCH
More informationImmunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of the unknown primary tumour (UPT) Part I Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Tumours of unknown origin: Histology Brain tumour - biopsy
More informationTHE STUDY ON RELATIONSHIP BETWEEN CIGARETTE SMOKING AND THE p53 PROTEIN AND P21 PROTEIN EXPRESSION IN NON-SMALL LUNG CANCER
( Thmese Journal of ('ancer Research 8(3): 187-19L 1996. THE STUDY ON RELATIONSHIP BETWEEN CIGARETTE SMOKING AND THE p53 PROTEIN AND P21 PROTEIN EXPRESSION IN NON-SMALL LUNG CANCER ZhouBaosen )~j'#:~ lleanguang
More informationQuality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024
Quality in Control ROS1 Analyte Control Product Codes: HCL022, HCL023 and HCL024 Contents What is ROS1? 2 The Role of ROS1 in Cancer 3 ROS1 Assessment 3 ROS1 Analyte Control Product Details 4 ROS1 Analyte
More informationImmunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD
Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationThe distinction of epithelioid mesotheliomas from adenocarcinomas
Immunohistochemical Diagnosis of Epithelioid Mesothelioma An Update Nelson G. Ordóñez, MD Objective. Several new immunohistochemical markers that can assist in the diagnosis of mesotheliomas have been
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationGuidelines for Pathologic Diagnosis of Malignant Mesothelioma. A Consensus Statement from the International Mesothelioma Interest Group
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma A Consensus Statement from the International Mesothelioma Interest Group Aliya N. Husain, MD; Thomas V. Colby, MD; Nelson G. Ordóñez, MD; Thomas
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in
More informationAntigen Receptor Structures October 14, Ram Savan
Antigen Receptor Structures October 14, 2016 Ram Savan savanram@uw.edu 441 Lecture #8 Slide 1 of 28 Three lectures on antigen receptors Part 1 (Today): Structural features of the BCR and TCR Janeway Chapter
More informationCase 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:
Case 18 M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is: A. Pilomatrical carcinoma B. Adnexal carcinoma NOS C. Metastatic squamous cell carcinoma D.Primary squamous cell carcinoma
More informationPancreatic Adenocarcinoma: What`s hot
Pancreatic Adenocarcinoma: What`s hot Eva Karamitopoulou-Diamantis Institute of Pathology University of Bern 11.09.2018, 30th ECP, Bilbao Pancreatic Cancer and the Microbiome The Pancreatic Cancer Microbiome
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationA Toriyama et al. 1 / 15 Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural,
A Toriyama et al. 1 / 15 Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural, and lung tumors: a comparison with polyclonal PAX8 antibody Akane Toriyama, 1,3 Taisuke
More informationGastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR
Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR Pages with reference to book, From 305 To 307 Irshad N. Soomro,Samina Noorali,Syed Abdul Aziz,Suhail Muzaffar,Shahid
More informationPathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download: http://testbankair.com/download/test-bank-for-robbins-cotran-pathologic-basis-of-disease-9th-edition-bykumar-abbas-and-aster Test Bank for Robbins and Cotran Pathologic Basis of Disease
More informationImmunohistochemical Evaluation of Necrotic Malignant Melanomas
Anatomic Pathology / EVALUATION OF NECROTIC MALIGNANT MELANOMAS Immunohistochemical Evaluation of Necrotic Malignant Melanomas Daisuke Nonaka, MD, Jordan Laser, MD, Rachel Tucker, HTL(ASCP), and Jonathan
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More informationMaterials and Methods , The two-hybrid principle.
The enzymatic activity of an unknown protein which cleaves the phosphodiester bond between the tyrosine residue of a viral protein and the 5 terminus of the picornavirus RNA Introduction Every day there
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationLung Cytology: Lessons Learned from Errors in Practice
Lung Cytology: Lessons Learned from Errors in Practice Stephen S. Raab, M.D. Department of Laboratory Medicine Eastern Health and Memorial University of Newfoundland, St. John s, NL and University of Washington,
More informationInterventional Pulmonary Case Based Discussions (ATS) Ali Imran Saeed, MD University of New Mexico
Interventional Pulmonary Case Based Discussions (ATS) Ali Imran Saeed, MD University of New Mexico Objectives Interventional Pulmonary in New Mexico Interventional Pulmonary and Advanced Diagnostic Cases
More informationMetastatic mechanism of spermatic cord tumor from stomach cancer
Int Canc Conf J (2013) 2:191 195 DOI 10.1007/s13691-013-0-9 CANCER BOARD CONFERENCE Metastatic mechanism of spermatic cord tumor from stomach cancer Masahiro Seike Yoshikazu Kanazawa Ryuji Ohashi Tadashi
More informationMalignant pleural mesothelioma (MPM) is a rare cancer,
Original Article CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions Christophe Blanquart, PhD,* Fabien Gueugnon, PhD,* Jean-Michel Nguyen, MD,* David Roulois,
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More informationCancer and Gene Alterations - 1
Cancer and Gene Alterations - 1 Cancer and Gene Alteration As we know, cancer is a disease of unregulated cell growth. Although we looked at some of the features of cancer when we discussed mitosis checkpoints,
More information57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
More informationSupplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in
Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Fig. 2 Substitution Sequence Position variant Sequence original APNCYGNIPL original APNCYGNIPL
More informationBiochemistry of Cancer and Tumor Markers
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
More informationAssessment of Confounding Factors Affecting the Tumor
Biomarker Insights O r i g i n a l R e s e a r c h Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Assessment of Confounding Factors Affecting the Tumor Markers
More informationCANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)
CANCER Affects 25% of US population Kills 19% of US population (2nd largest killer after heart disease) NOT one disease but 200-300 different defects Etiologic Factors In Cancer: Relative contributions
More informationFGL2 A new biomarker for cancer in a simple blood test
FGL2 A new biomarker for cancer in a simple blood test WHO IS FGL2 Human gene (chromosome 7) is 7 kb long, 2 exons, monomer protein 70 KD, tetramer in solution. Fibrinogen-like protein 2 (Fgl2), a member
More informationCutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationCancer genetics
Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1
More informationImmunohistochemical profile of normal mesothelium and histiocytic/methothelial hyperplasia: a case report
Int J Clin Exp Pathol 2011;4(6):631-636 www.ijcep.com /IJCEP1108006 Case Report Immunohistochemical profile of normal mesothelium and histiocytic/methothelial hyperplasia: a case report Tadashi Terada
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th
More informationImmunotoxin Therapy of Cancer Successes and Challenges
Immunotoxin herapy of Cancer Successes and Challenges Ira Pastan, David FitzGerald Raffit Hassan Robert Kreitman National Cancer Institute Background When naked antibodies fail, you can use them to target
More informationEndobronchial Ultrasound-guided Transbronchial Needle Aspiration in a Patient with Pericardial Mesothelioma
CASE REPORT Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in a Patient with Pericardial Mesothelioma Hironori Ashinuma 1, Masato Shingyoji 1, Yasushi Yoshida 1, Meiji Itakura 1, Fumihiro
More informationDiplomate of the American Board of Pathology in Anatomic and Clinical Pathology
A 33-year-old male with a left lower leg mass. Contributed by Shaoxiong Chen, MD, PhD Assistant Professor Indiana University School of Medicine/ IU Health Partners Department of Pathology and Laboratory
More informationMalignant Mesothelioma
Recent Results in Cancer Research 189 Malignant Mesothelioma Bearbeitet von Andrea Tannapfel 1. Auflage 2011. Buch. xii, 196 S. Hardcover ISBN 978 3 642 10861 7 Format (B x L): 16 x 24 cm Gewicht: 574
More informationThe role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
More informationSerous Effusions. Spasenija Savic Prince, MD Pathology, University Hospital Basel, Switzerland
Serous Effusions Spasenija Savic Prince, MD Pathology, University Hospital Basel, Switzerland Serous membrane Body cavities: Pleural Pericardial Peritoneal Effusion = Excess of fluid 80% Benign 20% Malignant
More information8 years later! Next Generation Sequencing. Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_ ) (VAF: 59%) HNF1A Loss
8 years later! Next Generation Sequencing Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_000545.6) (VAF: 59%) HNF1A Loss Interpretation HNF1A c.864delinscc, p.g292rfs*25 (NM_000545.6) This
More informationTriage of Ovarian Masses. Andreas Obermair Brisbane
Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led
More informationImmunohistochemistry in Peritoneal Mesothelioma. A Single-Center Experience of 244 Cases
Immunohistochemistry in Peritoneal Mesothelioma A Single-Center Experience of 244 Radhika Theresa Tandon, BS; Yuis Jimenez-Cortez, BA; Robert Taub, MD, PhD; Alain C. Borczuk, MD Context. Diagnosis of malignant
More information